"This is not an unfair report and is not biased to favor Novartis in some way."
I agree, whole-heartedly.
Basically, the question Credit Suisse asked was 'if Iclusig is only marginally better would you continue to prescribe Sprycel/Tasigna?' To no great surprise, most answered yes.
The one question I'm most interested in is 'if the 12 month, EPIC MMR is significantly better than the results achieved by Sprycel/Tasigna, would you prescribe Iclusig in a first or second-line setting?' I suspect that question would have a much different result than the one seen in the Credit Suisse survey.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.